What Vir Biotechnology, Inc. does.

Vir Biotechnology, Inc. (including its subsidiaries, referred to as “Vir Bio,” “the Company,” “we,” “our” or “us”) is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer.

These diseases represent formidable challenges to human health. Under normal conditions, our immune system is naturally equipped to protect us by identifying and eradicating both cancer cells and viruses. However, these threats have evolved sophisticated mechanisms to evade our immune defenses. When cancer cells or viruses successfully bypass our immune system, they have the potential to cause diseases that may be life-threatening. We are focused on developing therapies that enhance the immune system’s ability to overcome these evasion tactics, effectively powering the immune system to combat viruses and fight cancer.

We believe our unified approach of leveraging our deep understanding of immunology to address seemingly disparate threats distinguishes us in the field. Our mission is to develop innovative therapies that can transform patients' lives by addressing areas of high unmet medical need.

Revenue and profit, by fiscal year.

More on VIR.

• Vir Biotechnology, Inc. summary
• Vir Biotechnology, Inc. financial statements
• Vir Biotechnology, Inc. key metrics
• Vir Biotechnology, Inc. health scores and style box
• Vir Biotechnology, Inc. earnings
• Vir Biotechnology, Inc. dividends
• Vir Biotechnology, Inc. valuation
• Vir Biotechnology, Inc. ownership and insiders
• Vir Biotechnology, Inc. peers

Figures from Vir Biotechnology, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.